Anna Schuh, MD, PhD, MRCP, FRCPath of University of Oxford, Oxford, UK, discusses challenges associated with whole genome sequencing (WGS) data analysis. Big data centres are required to process and analyse the WGS information in combination with clinical outcome data. The WGS information can help identify patients, who could potentially die from side effects, be more sensitive to chemoimmunotherapy, have familial chronic lymphocytic leukemia (CLL), or suffer from autoimmune diseases as well as CLL. Dr Schuh mentions that the long term goal is to be able to link the WGS of the CLL patients to their extensive healthcare records in order to identify other potential problems, which may be genetically driven. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.